Previous 10 | Next 10 |
Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of personalized cancer immunotherapies for melanoma Announced gonorrhea as second bacterial product target Ended second quarter with cash and cash equivalents of $25.3 ...
Evaxion Biotech ( EVAX ) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in...
COPENHAGEN, Denmark, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced the following executive ma...
COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its s...
COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the Company has ident...
Evaxion Biotech A/S (NASDAQ: EVAX) a clinical-stage biotechnology company focused on the creation of AI-driven immunotherapies, announced today that it has chosen EVX-03 as the product candidate within its DNA technology platform to target a new indication with a planned regul...
Evaxion Biotech (EVAX) will advance DNA vaccine candidate EVX-03, under investigation for multiple cancer, for non-small cell lung cancer. The company expects a regulatory filing in this indication for a phase 1/2a trial in the second half of the year. Evaxion (EVAX) said that EVX-03 utilizes...
COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it has selected EVX-0...
Evaxion Biotech (EVAX) has entered into a committed equity purchase agreement with Lincoln Park Capital Fund, for the issuance and sale, from time to time, of up to $40M of its ADSs, each of which represents one ordinary share, DKK 1 nominal value, of the Co. Evaxion had cash and equivalents ...
COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that it has entered into ...
News, Short Squeeze, Breakout and More Instantly...
Evaxion Biotech A/S Company Name:
EVAX Stock Symbol:
NASDAQ Market:
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S ...
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promisi...
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completi...